AP NEWS

Human Vaccines 2016-2024 - Global Strategic Business Report 2018: Emerging Nations Offer Huge Opportunities for Pediatric Vaccine Manufacturers - ResearchAndMarkets.com

November 15, 2018

DUBLIN--(BUSINESS WIRE)--Nov 15, 2018--The “Human Vaccines - Global Strategic Business Reports” report has been added to ResearchAndMarkets.com’s offering.

The report provides separate comprehensive analytics for the US, Canada, Japan, Europe, Asia-Pacific, Latin America, and Rest of World. Annual estimates and forecasts are provided for the period 2016 through 2024. Also, a five-year historic analysis is provided for these markets.

This report analyzes the worldwide markets for Human Vaccines by the following Product Segments:Pediatric VaccinesAdult Vaccines

Company profiles are primarily based on public domain information including company URLs.

The report profiles 66 companies including many key and niche players such as:ALKAbell A/S (Denmark)Altimmune, Inc. (US)Bavarian Nordic A/S (Denmark)BiondVax Pharmaceuticals Ltd. (Israel)Bharat Biotech International Limited (India)GlaxoSmithKline Plc. (UK)Hualan Biological Engineering Inc. (China)Janssen Pharmaceuticals, Inc. (US)MedImmune (US)Merck & Co., Inc. (US)Pfizer Inc. (US)Sanofi Pasteur SA (France)Serum Institute of India Pvt. Ltd. (India)Shanghai BravoBio Co., Ltd. (China)Seqirus (UK)SK Chemicals Co., Ltd. (Korea)Takeda Pharmaceutical Company Limited (Japan)Zydus Cadila (India)

Key Topics Covered

1. MARKET OVERVIEW & OUTLOOKHuman Vaccines: A PreludeHuman Vaccines MarketA SnapshotMarket DynamicsGrowth Drivers in a CapsuleDeveloped World: The Key MarketsEmerging Markets: The Future Growth AreaVaccine Pricing: The DevelopedDeveloping Divide

2. MARKET TRENDS & ISSUES

Prophylactic Pediatric VaccinesA Mature MarketEmerging Nations Offer Huge Opportunities for Pediatric Vaccine ManufacturersRising Incidence of Infectious Diseases to Fuel Growth of Anti-Infective VaccinesNovel Vaccines against Emerging Infectious DiseasesOngoing Developments for a Vaccine against Zika VirusSanofi’s Dengue Vaccine First-to-MarketPipeline & Marketed Dengue Vaccine: 2016Computational Tools Come to Aid in Development of Ebola VaccinesVaccine for AIDSOngoing Research for HIV Vaccine & Commercial PipelineList of Clinical Trial (Phase II) AIDS Vaccines: 2015Staggering Global Statistics of AIDSOpportunity IndicatorVaccination-Autism Link and Other Safety Concerns ThwartedThreat of Pandemic Rejuvenates Vaccine MarketInfluenza Vaccines on a Growing SpreeInfluenza Vaccines on the Current Market: 2016H1N1 Vaccines Hit the Market in August 2009H1N1 Influenza Vaccines and ManufacturersInfluenza Market Faces Several ChallengesRising Disease Incidence and Increasing Awareness Drive the Global Meningococcal Vaccines MarketUnmet Demand for TB VaccineKey TB Vaccine Candidates in the Pipeline: 2016Need for a Human Vaccine for LeishmaniasisEconomic Factors Hamper Optimal Vaccine Development and DeliveryIncreasing Need for Vaccine Promotion in the Developing RegionsChanging Vaccine NeedsReligious Concerns over Immunizing Young Girls against Human PapillomavirusChanging Travel Patterns Increase Demand for Hepatitis B VaccineDNA Vaccines: Engineering GrowthNoninjectable Vaccines: Gain without PainApplication of Botulinum Toxin as Delivery Mechanism for Oral VaccinesConjugate Vaccines: A Technological InnovationHib Vaccines on the Market: 2016Growing Pricing PressureA Major Market DeterrentSafety Issues Come to the ForeBioWarfare: Threat Perception and PreparednessOverview of Potential Bio-Terrorist AgentsSmallpox (Variola Major)Anthrax (Bacillus Anthracis)Plague (Yersinia Pestis)Botulism (Clostridium Botulinum)Tularemia (Francisella Tularensis)Tackling Cold Chain IssuesTrade Statistics

3. COMPETITIVE LANDSCAPE

Pfizer Scores Big with PrevnarTrumenba Shows Promise in Phase III Clinical TrialsGSK Takes Big Leap into the Meningococcal Vaccine MarketAcquired Products Strengthen GSK’s Vaccines SalesThe Potential for MenABCWY VaccineSanofi Works on Production Issues to Boost SalesNew Vaccines to Enhance Prospects for SanofiSanofi’s Human Vaccine R&D PipelineWeaker Sales Drive Merck and Sanofi’s European JV SplitSerum Institute to Stir Competitive Landscape in the HPV Vaccine Market

4. PRODUCT OVERVIEW

5. CLINICAL TRIALS IN THE VACCINES MARKETInovio and GeneOne to Initiate Phase 1 Human Trial for Zika DNA VaccineTakeda Begins Phase2b Trial for World’s First Norovirus VaccineBavarian Nordic Announces Positive Results from Phase 1 Trial of RSV VaccineInvestigational Vaccine for P.vivax Malaria Enters Human TrialsValneva Reports Postive Phase 2 Results for Vaccine Candidate against C.difficileNovavax Announces Positive Phase 2 Clinical Trial Results for RSV-F Protein VaccineVical Reports Postive Preclinical Data for CyMVectin CMV vaccineProfectus BioSciences Receives HHS Contract to Accelerate Ebola Vaccine Candidate into Clinical StudiesInovio and GeneOne to Advance Ebola Vaccine into Phase 1 Trial

6. PRODUCT LAUNCHES/APPROVALS

FDA Approves 2016/17 Formulation of Protein Sciences Corporation’s FlublokSanofi’s Dengue Vaccine Approved in Costa RicaGSK Supplies Flu Vaccines based on Valneva’s EB66 Cell LineFDA Approves Seqirus’ FLUCELVAX QUADRIVALENT Influenza VaccineChina Launches HFMD VaccineBharat Biotech Introduces ZIKAVAC Vaccine for Zika InfectionSanofi Pasteur Launches Vaccine R&D Project for Zika Virus InfectionWHO Accepts Merck’s Investigational Ebola Vaccine Application for ReviewSanofi’s Dengvaxia Receives Marketing Authorization in MexicoSK Chemicals Launches Influenza Vaccine SKYCellfluSanofi Pasteur Ships First Doses of Fluzone for the US MarketBharat Biotech Launches Made-in-India ROTAVAC Vaccine

7. RECENT INDUSTRY ACTIVITY

WHO Prequalifies Four-dose, Multi-dose Vial Presentation of Pfizer’s Prevnar 13Sanofi Pasteur Begins Vaccine Manufacturing at Its Affiliate Shantha Biotechnics’ FacilityBavarian Nordic Announces IMVAMUNE Supply Contract with US GovernmentStellar Biotechnologies and Neovacs Form JV to Develop Conjugated VaccinesWHO Recommends Sanofi’s Dengvaxia in Nations with Widespread DengueKaketsuken to Sell Vaccines Business to AstellasSanofi and Merck End Joint Venture on VaccinesGeoVax Labs Collaborates with USAMRID for Hemorrhagic Fever VaccineBavarian Nordic Collaborates with Evaxion for Vaccine against MRSABavarian Nordic Enters into License Agreement with JanssenCSL Rebrands Influenza Vaccines Business as SeqirusMedImmune Joins Human Vaccines Project for Cancer and Infectious Disease Vaccine R&DGlaxoSmithKline Acquires Novartis’ Vaccines BusinessVaxin Changes Name to AltimmuneTakeda Expands Commercialization Agreement with NanotherapeuticsMedImmune Enters Into License Agreement with Inovio PharmaceuticalsCSL Completes Acquisition of Novartis’ Influenza Vaccines BusinessPfizer to Acquire Meningitis Vaccines from GSKPfizer Stops Prevnar Vaccine Sales in China After Government Fails to Renew License

8. FOCUS ON SELECT PLAYERS

9. GLOBAL MARKET PERSPECTIVE

Total Companies Profiled: 63 (including Divisions/Subsidiaries 72)The United States (22)Canada (1)Japan (5)Europe (14)France (3)Germany (2)The United Kingdom (2)Spain (1)Rest of Europe (6)

Asia-Pacific (Excluding Japan) (28)

Latin America (1)Middle East (1)

For more information about this report visit https://www.researchandmarkets.com/research/hcpmgn/human_vaccines?w=4

View source version on businesswire.com:https://www.businesswire.com/news/home/20181115005666/en/

CONTACT: ResearchAndMarkets.com

Laura Wood, Senior Press Manager

press@researchandmarkets.com

For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900

Related Topics:Vaccines

KEYWORD:

INDUSTRY KEYWORD: HEALTH INFECTIOUS DISEASES PHARMACEUTICAL

SOURCE: Research and Markets

Copyright Business Wire 2018.

PUB: 11/15/2018 11:01 AM/DISC: 11/15/2018 11:00 AM

http://www.businesswire.com/news/home/20181115005666/en

AP RADIO
Update hourly